A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma

A. Y.C. Chang, J. M. Bennett, K. J. Pandya, R. Asbury, C. McCune

Research output: Contribution to journalArticlepeer-review

Abstract

We have studied aminoglutethemide (AG) combined with hydrocortisone in 28 patients with advanced and refractory prostate carcinoma. All the patients had failed at least one endocrine therapy. Six patients received only one prior hormonal treatment. Five patients were off study within 3 weeks due to early death and toxicity, 14 had progressive disease, and 9 had stable disease. No objective partial remission was observed, but the nine stable patients had therapeutic benefit, with improvement in bone pain and performance status for a median duration of 153 days. Three patients withdrew because of postural hypotension, dizziness, weakness, and lethargy. The median survival of the entire group was 186 days (range 41-606 days). Our results suggest that aminoglutethemide and hydrocortisone can be alternative treatment for patients with advanced and refractory prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)358-360
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number4
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma'. Together they form a unique fingerprint.

Cite this